In recent years, studies showed that DEPDC1 was also aberrantly overexpressed in lung cancer, breast cancer, hepatocellular carcinomas and prostate cancer, and had prognostic value for predicting outcomes in patients with bladder cancer and lung cancer (9, 11–15). This evidence concerns the gene DEPDC1 and lung carcinoma.